Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
All content for MyeConversations by Myeloma Australia is the property of Myeloma Australia and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
S02 E9: MSAG and the partnership with Myeloma Australia
MyeConversations by Myeloma Australia
28 minutes
3 years ago
S02 E9: MSAG and the partnership with Myeloma Australia
In this episode we talk to Professor Miles Prince about the role of myeloma and Scientific Advisory Group (MSAG) in the myeloma space. We will get to know a bit more about the group and how they contribute to research, guidelines, new treatments and advocacy for people living with myeloma. We also examine the relationship between MSAG and Myeloma Australia and how they collaboratively work together to foster change and have a positive influence for people living with myeloma.
MyeConversations by Myeloma Australia
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
